National Institute of Mental Health 
Welcome,         Profile    Billing    Logout  
 0 Products   0 Diseases  0 Products   0 Trials   0 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
2R,6R-hydroxynorketamine hydrochloride ((2R,6R)-HNK) / National Institute of Mental Health
NCT06511908: Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Recruiting
2
50
US
(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
National Institute of Mental Health (NIMH)
Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
07/27
07/27
NCT04711005: Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

Completed
1
74
US
(2R,6R)-Hydroxynorketamine hydrochloride, Placebo
National Institute of Mental Health (NIMH)
Major Depressive Disorder
04/23
05/23

Download Options